Movement disorders in patients with central nervous system tuberculosis: A systematic review
Objective: We conducted a critical review of the literature on movement disorders (MD) in patients with central nervous (CNS) tuberculosis (TB), with the goal of…Identifying Barriers and Facilitators to Accessing Care for Members of the Black Diaspora and Hispanic People Affected by Parkinson Disease: A Qualitative Study
Objective: To identify barriers and facilitators to care for members of the Black Diaspora (MBD) and Hispanic people affected by Parkinson Disease (PD). To identify…Vegetables and fruits to relieve constipation: Do Parkinson’s disease patients know them?
Objective: To compare the knowledge of vegetables and fruits for treating constipation between PD and non-PD patients with constipation. Background: Constipation is a common non-motor…Real-World Retrospective Safety Analysis in Patients Treated With OnabotulinumtoxinA for Multiple Therapeutic Indications Over Repeat Treatment Periods
Objective: To evaluate the real-world safety of onabotulinumtoxinA (onabotA) use over repeat treatment periods (TPs) in patients (pts) with concomitant multiple therapeutic indications. Background: In…Movement Disorders in Anti-IGLON5 Antibody Disease
Objective: To review demographic, clinical features, treatment trends, and responses in Anti-IgLON5 disease with a focus on movement disorders Background: Anti-IgLON5 antibody disease has emerged…Instrument-supported Gait Analysis Characterizes Gait Domain Changes in Patients with Suspected Normal Pressure Hydrocephalus – a Retrospective Study
Objective: This study aimed at further characterizing the gait of patients with clinically suspected Normal Pressure Hydrocephalus (NPH) by investigating changes in several gait domains…Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Combining alpha-synuclein PET and seeded amplification assays to improve the diagnostic accuracy of Multiple System Atrophy of the Parkinsonian subtype (MSA-P)
Objective: To determine whether the combination of spatial (PET [18F]ACI-12589) and conformational (skin seed amplification assay; SAA) a-syn data aids the early differential diagnosis of…Is cathepsin D a good target for therapy in Tau-related conditions?
Objective: To study the involvement of cathepsin D in the pathogenesis of Tau-related conditions. Background: The endo-lysosomal system (ELS) is central in processing of neurodegenerative…Identification of underlying Lewy body pathology in primary tauopathies by α-synuclein seed amplification assay
Objective: To determine intravitam prevalence of α-synuclein (αSyn) pathology in primary tauopathies, such as PSP and CBS, by αSyn seed amplification assay (synSAA) Background: Neuropathological…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 181
- Next Page »